Combating Infectious Diseases Key Focus of AACC
|
By LabMedica International staff writers Posted on 03 Aug 2017 |
At the 69th AACC Annual Scientific Meeting & Clinical Lab Expo, the world’s largest exposition for clinical laboratory products and services, over 750 exhibitors displayed pioneering diagnostic technology, including the latest in mobile health, molecular diagnostics, mass spectrometry, point-of-care, and automation, with the focus being largely on speed and effectiveness in infectious disease detection.
According to Kalorama Information, (New York, NY, USA), an independent medical market research firm, diseases caused by infection are among the largest and most competitive markets for in vitro diagnostics (IVD) instruments, kits and reagents. The 2017 AACC Clinical Lab Expo held at the San Diego Convention Center from July 30–August 3, saw important product announcements for early and accurate detection for the treatment of infectious diseases.
Some of the product announcements at the event included a new method for detecting 5 gram-negative bacteria using genoproteomic peptide marker analysis on a combined MS/LC system. Additionally, Ortho Clinical Diagnostics showcased its Vitros Immunodiagnostic Products human immunodeficiency virus (HIV) combo assay for use on the Vitros 3600 immunodiagnostic system. A fourth-generation HIV assay, the Vitros HIV combo is designed to detect acute HIV-1 infection earlier than previous generations of HIV assays.
Further, Aalto Bio Reagents, a developer and provider of raw materials to the in- vitro diagnostics industry and to research laboratories globally, announced their first-to-market recombinant Yellow Fever Virus (YFV) protein. Also, Seegene Inc. announced a Random Access System, which can provide order-to-report on the same day by simultaneously performing high multiplex real-time PCR testing on a single platform, regardless of specimen type or assays.
Related Links:
Kalorama Information
According to Kalorama Information, (New York, NY, USA), an independent medical market research firm, diseases caused by infection are among the largest and most competitive markets for in vitro diagnostics (IVD) instruments, kits and reagents. The 2017 AACC Clinical Lab Expo held at the San Diego Convention Center from July 30–August 3, saw important product announcements for early and accurate detection for the treatment of infectious diseases.
Some of the product announcements at the event included a new method for detecting 5 gram-negative bacteria using genoproteomic peptide marker analysis on a combined MS/LC system. Additionally, Ortho Clinical Diagnostics showcased its Vitros Immunodiagnostic Products human immunodeficiency virus (HIV) combo assay for use on the Vitros 3600 immunodiagnostic system. A fourth-generation HIV assay, the Vitros HIV combo is designed to detect acute HIV-1 infection earlier than previous generations of HIV assays.
Further, Aalto Bio Reagents, a developer and provider of raw materials to the in- vitro diagnostics industry and to research laboratories globally, announced their first-to-market recombinant Yellow Fever Virus (YFV) protein. Also, Seegene Inc. announced a Random Access System, which can provide order-to-report on the same day by simultaneously performing high multiplex real-time PCR testing on a single platform, regardless of specimen type or assays.
Related Links:
Kalorama Information
Latest AACC 2017 News
- Siemens Healthineers Showcases Atellica Solution at AACC 2017
- Ortho Clinical Diagnostics Highlights Immunodiagnostics at Clinical Expo
- World's First Fully Integrated LC-MS/MS Clinical Analyzer Unveiled
- Clinical Chemistry Analyzer Provides DAU Screening
- Diatron Displays New Hematology Analyzer at UAE Congress
- Microscan Demonstrates Advanced Technology at Scientific Meeting
- AACC Middle East to Be Held in Abu Dhabi
- AACC 2017 Focus on CRISPR and Futuristic Testing Devices
- Opioid Drug Abuse Testing Key Topic at Congress
- Keynote Address to Focus on CRISPR/Cas9 Gene Editing
- Winner of Qualcomm Tricorder XPrize Unveiled at AACC
- Annual Meeting Offers Industry Education and Entertainment
Channels
Clinical Chemistry
view channel
Saliva-Based Test Detects Biochemical Signs of Sleep Loss
Acute sleep loss impairs cognition and motor skills, raising safety risks that resemble alcohol intoxication. Clinicians currently lack an objective biochemical test to determine when someone is dangerously... Read more
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Plasma Protein Signature Predicts Lung Cancer Risk Up to Five Years Ahead
Lung cancer remains a leading cause of cancer death, and many cases are detected only after symptoms appear. Current screening programs largely target people with a history of smoking, leaving other at-risk... Read more
Circulating Tumor DNA Testing Guides Chemotherapy, Reduces Relapse in Colon Cancer
Adjuvant therapy decisions after curative surgery for colon cancer remain difficult, as conventional clinicopathologic factors often fail to capture residual disease risk. Liquid biopsy approaches that... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channelAptamer-Based Biosensor Enables Mutation-Resilient SARS-CoV-2 Detection
Rapid evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can undermine existing molecular diagnostics, especially when assays target small viral components. Double-antibody sandwich... Read more
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read moreMicrobiology
view channel
Gut Microbiome Signatures Help Identify Risk of IBD Progression
Inflammatory bowel disease (IBD), encompassing Crohn’s disease and ulcerative colitis, is a chronic relapsing inflammatory disorder of the gastrointestinal tract with highly variable outcomes.... Read more
FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
Clinical guidelines support testing based on patient presentation in suspected gastrointestinal infections, yet available technologies have often forced laboratories to choose between panels that are too... Read morePathology
view channel
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read more
FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
Clinical laboratories play a central role in guiding immunotherapy by reporting programmed death ligand-1 (PD‑L1) status across multiple solid tumors. Many sites are standardizing this work on fully automated... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel









